372 related articles for article (PubMed ID: 22481011)
1. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia.
Marai I; Khoury A; Suleiman M; Gepstein L; Blich M; Lorber A; Boulos M
Am J Cardiol; 2012 Jul; 110(1):72-6. PubMed ID: 22481011
[TBL] [Abstract][Full Text] [Related]
2. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
Roses-Noguer F; Jarman JW; Clague JR; Till J
Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate.
Miyake CY; Webster G; Czosek RJ; Kantoch MJ; Dubin AM; Avasarala K; Atallah J
Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):579-87. PubMed ID: 23667268
[TBL] [Abstract][Full Text] [Related]
5. Ten-year follow-up of cardiac sympathectomy in a young woman with catecholaminergic polymorphic ventricular tachycardia and an implantable cardioverter defibrillator.
Makanjee B; Gollob MH; Klein GJ; Krahn AD
J Cardiovasc Electrophysiol; 2009 Oct; 20(10):1167-9. PubMed ID: 19298566
[TBL] [Abstract][Full Text] [Related]
6. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
7. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest.
van der Werf C; Lieve KV; Bos JM; Lane CM; Denjoy I; Roses-Noguer F; Aiba T; Wada Y; Ingles J; Leren IS; Rudic B; Schwartz PJ; Maltret A; Sacher F; Skinner JR; Krahn AD; Roston TM; Tfelt-Hansen J; Swan H; Robyns T; Ohno S; Roberts JD; van den Berg MP; Kammeraad JA; Probst V; Kannankeril PJ; Blom NA; Behr ER; Borggrefe M; Haugaa KH; Semsarian C; Horie M; Shimizu W; Till JA; Leenhardt A; Ackerman MJ; Wilde AA
Eur Heart J; 2019 Sep; 40(35):2953-2961. PubMed ID: 31145795
[TBL] [Abstract][Full Text] [Related]
8. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
[TBL] [Abstract][Full Text] [Related]
9. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
[TBL] [Abstract][Full Text] [Related]
10. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
[TBL] [Abstract][Full Text] [Related]
11. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
Watanabe H; Knollmann BC
J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
[TBL] [Abstract][Full Text] [Related]
12. Incidence and causes of inappropriate detection and therapy by implantable defibrillators of cardioversion in patients with ventricular tachyarrhythmia.
Chen RH; Chen KP; Wang FZ; Hua W; Chen X; Zhang S
Chin Med J (Engl); 2006 Apr; 119(7):557-63. PubMed ID: 16620696
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia.
Glikson M; Lipchenca I; Viskin S; Ballman KV; Trusty JM; Gurevitz OT; Luria DM; Eldar M; Hammill SC; Friedman PA
J Cardiovasc Electrophysiol; 2004 Jun; 15(6):658-64. PubMed ID: 15175060
[TBL] [Abstract][Full Text] [Related]
14. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy.
O'Mahony C; Lambiase PD; Rahman SM; Cardona M; Calcagnino M; Quarta G; Tsovolas K; Al-Shaikh S; McKenna W; Elliott P
Europace; 2012 May; 14(5):724-33. PubMed ID: 22094454
[TBL] [Abstract][Full Text] [Related]
15. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review.
Roston TM; Jones K; Hawkins NM; Bos JM; Schwartz PJ; Perry F; Ackerman MJ; Laksman ZWM; Kaul P; Lieve KVV; Atallah J; Krahn AD; Sanatani S
Heart Rhythm; 2018 Dec; 15(12):1791-1799. PubMed ID: 30063211
[TBL] [Abstract][Full Text] [Related]
16. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
Hayashi M; Denjoy I; Extramiana F; Maltret A; Buisson NR; Lupoglazoff JM; Klug D; Hayashi M; Takatsuki S; Villain E; Kamblock J; Messali A; Guicheney P; Lunardi J; Leenhardt A
Circulation; 2009 May; 119(18):2426-34. PubMed ID: 19398665
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
[TBL] [Abstract][Full Text] [Related]
19. [Implantable cardioverter-defibrillators in the prevention of sudden cardiac death].
Kozák M; Krivan L; Semrád B
Vnitr Lek; 2001 Jun; 47(6):361-70. PubMed ID: 11494881
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
